Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTMT1 | Q9BV86 | 20/20 | 0.64 |
| ▸ | UGCG | Q16739 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614566 | 1.00 | NTMT1 (0.64) | NTMT1UGCG | |
| SCHEMBL12615326 | 0.81 | NTMT1 (0.71) | NTMT1UGCG | |
| SCHEMBL12615324 | 0.81 | NTMT1 (0.71) | NTMT1UGCG | |
| SCHEMBL31522582 | 0.79 | NTMT1 (0.61) | NTMT1UGCG | |
| SCHEMBL12613996 | 0.79 | NTMT1 (0.67) | NTMT1UGCG | |
| SCHEMBL29387425 | 0.78 | NTMT1 (0.61) | NTMT1UGCG | |
| SCHEMBL19844441 | 0.78 | NTMT1 (0.61) | NTMT1UGCG | |
| SCHEMBL19844440 | 0.78 | NTMT1 (0.61) | NTMT1UGCG | |
| SCHEMBL12696495 | 0.78 | NTMT1 (0.61) | NTMT1UGCG | |
| Venglustat SCHEMBL12615329 | 0.78 | NTMT1 (1.00) | NTMT1UGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GENZYME CORPORATION (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3920912-B1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GENZYME CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| EP-4349408-A2 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-3267983-B1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORP (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GENZYME CORPORATION | 2023-11-23 | — | — | US | disclosed |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GENZYME CORPORATION (US) | 2022-04-14 | — | — | US | disclosed |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-27 | — | — | US | disclosed |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GENZYME CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION | 2018-02-08 | — | — | US | disclosed |
| EP-3267983-A1 | METHODS FOR TREATING PROTEINOPATHIES | Genzyme Corporation (US) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016145046-A1 | METHODS FOR TREATING PROTEINOPATHIES | GENZYME CORPORATION (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2016-07-21 | — | — | US | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
| EP-2685986-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012129084-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527776-B2 | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS) | GBA1, GBA2, GALC | NTMT1 1645/4885UGCG 20/4885 |
| US-12083115-B2 | Methods for treating neurological symptoms associated with lysosomal storage diseases | GBA1, GBA2, CLN6 | NTMT1 1309/4885UGCG 147/4885 |
| US-20230372313-A1 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | GBA1, GBA2, GALC | NTMT1 684/4885UGCG 13/4885 |
| US-20220016092-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, GALC | NTMT1 2471/4885UGCG 84/4885 |
| US-20220110922-A1 | TREATMENT OF CILIOPATHIES USING INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE (GCS) | GBA1, GBA2, GALC | NTMT1 1692/4885UGCG 4/4885 |
| US-20160207933-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 814/4885UGCG 4/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 814/4885UGCG 4/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | NTMT1 814/4885UGCG 4/4885 |
| US-20220023273-A1 | METHODS FOR TREATING SYMPTOMS AND DISORDERS ASSOCIATED WITH LYSOSOMAL STORAGE DISEASES | GAA, GBA1, CMA1 | NTMT1 1379/4885UGCG 160/4885 |
| US-20180036295-A1 | METHODS FOR TREATING PROTEINOPATHIES | SNCA, PRNP, PARK7 | NTMT1 1778/4885UGCG 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.